TREM2 Protein

TREM2 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TREM2 Protein</th>
</tr>
<tr>
<td class="label">Year</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">2013</td>
<td>TREM2 variants R47H increase AD risk 3-4x</td>
</tr>
<tr>
<td class="label">2015</td>
<td>TREM2 required for Aβ plaque-associated microgliosis</td>
</tr>
<tr>
<td class="label">2017</td>
<td>sTREM2 detectable in CSF, associated with AD biomarkers</td>
</tr>
<tr>
<td class="label">2019</td>
<td>TREM2 agonists show promise in preclinical models</td>
</tr>
<tr>
<td class="label">2021</td>
<td>TREM2 affects tau pathology progression</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-seaad-51323624" style="color:#ce93d8" title="Score: 0.73">Cell-Type Specific TREM2 Upregulation in...</a><br><a href="/hypothesis/h-180807e5" style="color:#ce93d8" title="Score: 0.70">APOE-TREM2 Interaction Modulation...</a><br><a href="/hypothesis/h-3460f820" style=

TREM2 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TREM2 Protein</th>
</tr>
<tr>
<td class="label">Year</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">2013</td>
<td>TREM2 variants R47H increase AD risk 3-4x</td>
</tr>
<tr>
<td class="label">2015</td>
<td>TREM2 required for Aβ plaque-associated microgliosis</td>
</tr>
<tr>
<td class="label">2017</td>
<td>sTREM2 detectable in CSF, associated with AD biomarkers</td>
</tr>
<tr>
<td class="label">2019</td>
<td>TREM2 agonists show promise in preclinical models</td>
</tr>
<tr>
<td class="label">2021</td>
<td>TREM2 affects tau pathology progression</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-seaad-51323624" style="color:#ce93d8" title="Score: 0.73">Cell-Type Specific TREM2 Upregulation in...</a><br><a href="/hypothesis/h-180807e5" style="color:#ce93d8" title="Score: 0.70">APOE-TREM2 Interaction Modulation...</a><br><a href="/hypothesis/h-3460f820" style="color:#ce93d8" title="Score: 0.58">TREM2-Mediated Selective Aggregate Clear...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1914 edges</a></td>
</tr>
</table>

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a cell-surface receptor predominantly expressed on [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system. TREM2 plays a critical role in microglial function, including phagocytosis, cell survival, inflammation regulation, and metabolic adaptation. Genetic variants in TREM2 are strongly associated with Alzheimer's disease (AD) risk, making it one of the most significant genetic discoveries in AD research in recent decades[@jonsson2013].

The TREM2 gene encodes a type I transmembrane protein with an extracellular immunoglobulin-like domain, a transmembrane region, and a short cytoplasmic tail. Upon ligand binding, TREM2 signals through the adaptor protein DAP12 (TYROBP), triggering downstream signaling cascades that regulate microglial homeostasis and response to neurodegeneration[@wang2015].

Structure and Molecular Biology

Protein Structure

TREM2 is a 35 kDa glycoprotein belonging to the immunoglobulin superfamily. The extracellular domain consists of a single V-type immunoglobulin-like fold that mediates ligand binding. The protein is expressed as a membrane-bound form and can be proteolytically cleaved to release a soluble fragment (sTREM2) that retains functional activity[@kober2016].

Key structural features include:

• Extracellular domain: Ig-like V-type domain responsible for ligand recognition
• Transmembrane domain: Contains a positively charged residue (lysine) that interacts with the negatively charged aspartic acid in the DAP12 transmembrane helix
• Cytoplasmic tail: Short intracellular domain lacking inherent signaling motifs; relies on DAP12 for signal transduction

Ligands

TREM2 recognizes multiple ligands relevant to neurodegenerative conditions:

• Lipids: Phospholipids, sphingolipids, and apolipoproteins (ApoE, ApoJ) released from damaged cells
• Aβ oligomers: Amyloid-beta plaques bind to TREM2, triggering microglial responses
• TREM2 ligands on neurons: Exposed on stressed or dying neurons
• Bacterial components: TREM2 can recognize microbial lipids, linking innate immunity to infection responses[@yeh2016]

Role in Alzheimer's Disease

Genetic Association

Rare coding variants in TREM2 significantly increase AD risk:

• R47H (Arg47His): Increases AD risk by ~3-4 fold, similar to APOE ε4
• R62H: Moderate risk increase
• H157Y: Associated with earlier onset
• Y38C: Loss-of-function variant

Microglial Dysfunction in AD

TREM2 deficiency leads to several microglial defects:

TREM2 and Tau Pathology

Beyond Aβ, TREM2 also influences tau pathology progression. Microglial activation can either protect against tau spread (by clearing tau-containing neurons) or exacerbate it (through release of inflammatory mediators). TREM2's role appears to be protective, as TREM2 deficiency leads to increased tau phosphorylation and spread in mouse models[@shi2019].

TREM2 in Parkinson's Disease

While most intensively studied in AD, TREM2 also plays a role in [Parkinson's disease](/diseases/parkinsons-disease). TREM2 variants have been associated with PD risk in some populations, and TREM2 signaling affects microglial responses to alpha-synuclein pathology. The TREM2-DAP12 pathway influences neuroinflammation in PD models, though the relationship is more complex than in AD[@hu2020].

Soluble TREM2 (sTREM2)

The extracellular domain of TREM2 can be shed by proteases (primarily ADAM10/17), releasing a soluble form (sTREM2) into cerebrospinal fluid and blood. sTREM2:

• Reflects TREM2 expression and processing
• Has biological activity, potentially acting as a decoy or signaling molecule
• Is being investigated as a biomarker for AD and other neurodegenerative diseases
• CSF sTREM2 levels change with disease stage and may predict progression[@suarezcalvet2016]

Therapeutic Implications

TREM2 Agonists

Small molecules and antibodies that activate TREM2 are being developed as potential AD therapies:

• AL002: Anti-TREM2 agonist antibody (Alector/AbbVie) - showed safety in Phase 1, progressed to Phase 2
• PY314: TREM2-targeting antibody (Pyramid Biosciences)
• Small molecule activators: Under development to enhance TREM2 signaling

TREM2 Deficiency Model

Studies in TREM2 knockout mice demonstrate that microglial activation without proper TREM2 signaling can be detrimental, emphasizing the need for agonists rather than antagonists[@price2019].

Biomarker Development

sTREM2 measurement in CSF and plasma is being validated as a:

• Diagnostic marker for AD
• Prognostic marker for disease progression
• Pharmacodynamic marker for TREM2-targeting therapies

Signaling Pathway

TREM2 signals through DAP12 (DNAX-activating protein of 12 kDa), an adaptor protein containing an immunoreceptor tyrosine-based activation motif (ITAM). Upon TREM2 engagement:

• Cytokine production
• Phagocytosis machinery
• Cell survival pathways
• Metabolic genes

Key Research Findings

Cross-References

• [TREM2 Gene](/genes/trem2) - Genetic overview and variants
• [Microglia](/cell-types/microglia-neuroinflammation) - Cell type expressing TREM2
• [Alzheimer's Disease](/diseases/alzheimers-disease) - Disease with strongest TREM2 association
• [Neuroinflammation](/mechanisms/neuroinflammation) - Role of TREM2 in inflammation
• [Microglial Activation](/mechanisms/microglial-activation) - TREM2-mediated activation
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade) - Interaction with Aβ pathology

See Also

• [Parkinson's disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Microglial Activation](/mechanisms/microglial-activation)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
• [Allen Human Brain Atlas - TREM2 Expression](https://human.brain-map.org/microarray/search/show?search_term=TREM2)
• [Allen Cell Type Atlas - TREM2](https://celltypes.brain-map.org/)
• [Allen Mouse Brain Atlas - TREM2](https://mouse.brain-map.org/)
• [BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/)

References

Recent Research Advances (2025-2026)

Recent studies have significantly advanced our understanding of TREM2 biology and its therapeutic potential:

• 2026: TREM2 biomarker studies reveal CSF sTREM2 as a dynamic marker of disease progression and treatment response
• 2025: Phase 2 trials of TREM2 agonist AL002 show modulation of microglial activation markers in early AD patients
• 2025: Structural studies reveal TREM2 ligand-binding mechanics, informing agonist design
• 2025: Novel TREM2 variants identified with differential effects on AD risk
• 2024: Spatial proteomics characterizes TREM2 expression patterns in human AD brain
• 2024: Combined TREM2 and anti-amyloid therapy shows enhanced efficacy in preclinical models

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TREM2
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ff8a65;font-weight:600">0.40</span> · Target: TREM2

Pathway Diagram

The following diagram shows the key molecular relationships involving TREM2 Protein discovered through SciDEX knowledge graph analysis: